Contineum Therapeutics, Inc.: Johnson & Johnson Innovation - JJDC, Inc. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Johnson & Johnson Innovation–JJDC filed an amended Schedule 13G with the SEC (accession 0000904454-26-000591) updating its beneficial ownership stake in Contineum Therapeutics. The filing, a short-form statement reserved for passive investors, revises JJDC's previously reported position in the clinical-stage biotech. The amendment signals a change in the size of J&J's holding, though the headline did not disclose the specific percentage or share count. Investors will watch for the full filing details to gauge whether J&J increased or trimmed its stake, a signal of its confidence in Contineum's pipeline.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Contineum Therapeutics, Inc., Johnson & Johnson Innovation - JJDC, Inc.